Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
Mohammad Mehdi Ghahremanpour, Julian Tirado‐Rives, M.G. Deshmukh, Joseph A. Ippolito, Chunhui Zhang, Israel Cabeza de Vaca, Maria-Elena Liosi, Karen S. Anderson, William L. Jorgensen
Abstract
. Further study of the most active compounds in the context of COVID-19 therapy is warranted, while all of the active compounds may provide a foundation for lead optimization to deliver valuable chemotherapeutics to combat the pandemic.
Topics & Concepts
Context (archaeology)ProteaseVirtual screeningPharmacologyCoronavirus disease 2019 (COVID-19)BoceprevirChemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Computational biologyMedicineEnzymeVirologyVirusBiochemistryBiologyDrug discoveryInternal medicineHepatitis C virusPaleontologyDiseaseInfectious disease (medical specialty)RibavirinComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 ResearchSynthesis and biological activity